Vantis Vascular has successfully closed a $10 million Series B-1 funding round, bringing its total funding to $30 million. Based in San Jose, California, the company is focused on advancing interventional cardiology with its CrossFast microcatheter guide extension system and CrossShock intravascular lithotripsy (IVL) system.
Innovative Technology for Complex Procedures
The CrossFast system, powered by DuoPro interlocking technology, offers:
- Enhanced pushability and navigation for challenging anatomies.
- A guide extension catheter that provides additional support for complex and high-risk procedures.
Following FDA clearance in October, CrossFast is now available on a limited basis in the U.S., with plans for a full commercial launch next year.
CEO Statement
Jason Turner, CEO of Vantis Vascular, emphasized the significance of the funding:
“This funding is a critical milestone for Vantis and will allow us to continue product development, expand our team, and initiate U.S. commercialization of the CrossFast advanced delivery system for complex high-risk PCI procedures.”
Driving Transformations in Cardiology
With its innovative solutions and strategic funding, Vantis Vascular is set to redefine complex interventional procedures, offering physicians advanced tools for safer and more efficient patient care.
Stay updated with MEDWIRE.AI for the latest breakthroughs in MedTech innovation.
